Relypsa Company Profile (NASDAQ:RLYP)

About Relypsa (NASDAQ:RLYP)

Relypsa logoRelypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RLYP
  • CUSIP: N/A
  • Web: www.relypsa.com/
Average Prices:
  • 50 Day Moving Avg: $30.31
  • 200 Day Moving Avg: $20.28
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.13
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -1,601.53%
  • Return on Equity: -227.26%
  • Return on Assets: -115.06%
Misc:
  • Beta: 2.19
 

Frequently Asked Questions for Relypsa (NASDAQ:RLYP)

What is Relypsa's stock symbol?

Relypsa trades on the NASDAQ under the ticker symbol "RLYP."

How were Relypsa's earnings last quarter?

Relypsa Inc (NASDAQ:RLYP) announced its earnings results on Wednesday, May, 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.46) by $0.20. The company had revenue of $12.40 million for the quarter, compared to the consensus estimate of $6.88 million. Relypsa had a negative net margin of 1,601.53% and a negative return on equity of 227.26%. During the same period in the previous year, the business earned ($0.78) EPS. View Relypsa's Earnings History.

Who are some of Relypsa's key competitors?

How do I buy Relypsa stock?

Shares of Relypsa can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Relypsa's stock price today?

One share of Relypsa stock can currently be purchased for approximately $31.99.


MarketBeat Community Rating for Relypsa (NASDAQ RLYP)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  529
MarketBeat's community ratings are surveys of what our community members think about Relypsa and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Relypsa (NASDAQ:RLYP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Relypsa (NASDAQ:RLYP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/1/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
9/1/2016WedbushDowngradeOutperform -> Neutral$32.00N/AView Rating Details
8/22/2016Stifel NicolausDowngradeBuy -> Hold$32.00N/AView Rating Details
8/13/2016MizuhoReiterated RatingNeutral$32.00N/AView Rating Details
8/8/2016Cantor FitzgeraldReiterated RatingHold$32.00N/AView Rating Details
7/22/2016HC WainwrightDowngradeBuy -> Neutral$32.00N/AView Rating Details
7/21/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$9.00 -> $32.00N/AView Rating Details
7/21/2016Citigroup Inc.DowngradeBuy -> Neutral$25.00 -> $32.00N/AView Rating Details
7/21/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
5/31/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$36.00N/AView Rating Details
5/29/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
4/1/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
2/25/2016Bank of America CorporationReiterated RatingBuy$32.00 -> $29.00N/AView Rating Details
11/4/2015GuggenheimInitiated CoverageBuy$46.00N/AView Rating Details
10/27/2015NomuraReiterated RatingOutperform$75.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Relypsa (NASDAQ:RLYP)
Earnings by Quarter for Relypsa (NASDAQ:RLYP)
Earnings History by Quarter for Relypsa (NASDAQ RLYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2016Q1($1.46)($1.26)$6.88 million$12.40 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.40)$7.37 million$11.96 millionViewListenView Earnings Details
11/4/2015Q3($0.89)($1.24)$6.67 million$6.50 millionViewN/AView Earnings Details
8/6/2015($0.95)($0.95)$0.01 millionViewN/AView Earnings Details
5/7/2015($0.87)($0.78)ViewN/AView Earnings Details
3/11/2015Q414($0.68)($0.80)ViewN/AView Earnings Details
11/10/2014($0.61)($0.57)ViewN/AView Earnings Details
8/11/2014($0.57)($0.51)ViewN/AView Earnings Details
5/7/2014($0.56)($0.54)ViewN/AView Earnings Details
3/17/2014Q413($0.50)($0.68)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Relypsa (NASDAQ:RLYP)
2017 EPS Consensus Estimate: ($6.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.65)($1.65)($1.65)
Q2 20171($1.64)($1.64)($1.64)
Q3 20171($1.62)($1.62)($1.62)
Q4 20171($1.59)($1.59)($1.59)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Relypsa (NASDAQ:RLYP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Relypsa (NASDAQ:RLYP)
Insider Trades by Quarter for Relypsa (NASDAQ:RLYP)
Institutional Ownership by Quarter for Relypsa (NASDAQ:RLYP)
Insider Trades by Quarter for Relypsa (NASDAQ:RLYP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2016James D DonderoMajor ShareholderBuy500$31.92$15,960.00View SEC Filing  
8/16/2016Monte MontgomeryInsiderSell510$31.92$16,279.20View SEC Filing  
8/11/2016James D DonderoMajor ShareholderSell37,000$31.96$1,182,520.00View SEC Filing  
7/25/2016Orbimed Advisors LlcMajor ShareholderSell4,043,600$32.00$129,395,200.00View SEC Filing  
6/7/2016David W J McgirrDirectorSell1,013$19.34$19,591.42View SEC Filing  
3/16/2016Kristine M BallCFOBuy7,000$12.15$85,050.00View SEC Filing  
3/15/2016Thomas J SchuetzDirectorBuy30,000$13.39$401,700.00View SEC Filing  
12/31/2015Wilhelm StahlSVPSell20,000$28.53$570,600.00View SEC Filing  
12/23/2015Orbimed Advisors LlcMajor ShareholderSell500,000$27.18$13,590,000.00View SEC Filing  
12/9/2015Lance BermanSVPSell750$29.50$22,125.00View SEC Filing  
12/7/2015John A. OrwinCEOSell15,000$28.28$424,200.00View SEC Filing  
12/7/2015Lance BermanSVPSell30,000$29.78$893,400.00View SEC Filing  
12/4/2015John A. OrwinCEOSell40,000$25.00$1,000,000.00View SEC Filing  
10/22/2015Orbimed Advisors LlcMajor ShareholderBuy500,000$12.56$6,280,000.00View SEC Filing  
8/17/2015John A OrwinCEOSell5,000$24.84$124,200.00View SEC Filing  
8/17/2015Lance BermanSVPSell710$24.77$17,586.70View SEC Filing  
8/17/2015Ronald A KrasnowInsiderSell522$24.75$12,919.50View SEC Filing  
6/11/2015Thomas J SchuetzDirectorSell1,000$34.57$34,570.00View SEC Filing  
6/1/2015John A OrwinCEOSell33,555$36.42$1,222,073.10View SEC Filing  
5/18/2015Orbimed Advisors LlcMajor ShareholderSell1,457,551$34.13$49,746,215.63View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell5,834$36.06$210,374.04View SEC Filing  
4/10/2015Klaus R Dr VeitingerDirectorSell5,832$35.35$206,161.20View SEC Filing  
3/5/2015Kristine M BallCFOSell3,519$40.68$143,152.92View SEC Filing  
2/27/2015Ronald A KrasnowInsiderSell10,348$39.00$403,572.00View SEC Filing  
2/24/2015Lance BermanSVPSell5,000$38.19$190,950.00View SEC Filing  
2/24/2015Ronald A KrasnowInsiderSell10,000$39.00$390,000.00View SEC Filing  
2/10/2015Klaus R Dr VeitingerDirectorSell5,834$32.12$187,388.08View SEC Filing  
1/21/2015Claire LockeyInsiderSell5,000$35.00$175,000.00View SEC Filing  
1/21/2015Kristine M BallCFOSell3,000$36.00$108,000.00View SEC Filing  
1/14/2015Ronald A KrasnowInsiderSell5,000$33.58$167,900.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell5,834$32.33$188,613.22View SEC Filing  
12/12/2014Klaus R Dr VeitingerDirectorSell14,169$32.16$455,675.04View SEC Filing  
12/9/20145Am Partners Iii, LlcMajor ShareholderSell589,637$30.04$17,712,695.48View SEC Filing  
12/9/2014Claire LockeyInsiderSell8,000$30.00$240,000.00View SEC Filing  
11/25/2014Lance BermanSVPSell30,000$25.00$750,000.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell2,500$19.34$48,350.00View SEC Filing  
9/24/2014Lance BermanSVPSell5,000$22.00$110,000.00View SEC Filing  
9/17/2014Orbimed Advisors LlcMajor ShareholderSell94,000$25.27$2,375,380.00View SEC Filing  
9/16/20145Am Partners Ii, LlcMajor ShareholderSell612,540$26.03$15,944,416.20View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.00$95,841.00View SEC Filing  
8/29/2014Wilhelm StahlSVPSell15,785$25.29$399,202.65View SEC Filing  
8/26/20145Am Partners Ii, LlcMajor ShareholderSell433,000$26.51$11,478,830.00View SEC Filing  
8/25/2014Lance BermanSVPSell20,000$25.89$517,800.00View SEC Filing  
8/11/2014Klaus R Dr VeitingerDirectorSell4,167$27.73$115,550.91View SEC Filing  
7/24/2014Lance BermanSVPSell45,000$23.92$1,076,400.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.12$96,341.04View SEC Filing  
11/20/20135Am Partners Iii, LlcMajor ShareholderBuy372,692$11.00$4,099,612.00View SEC Filing  
11/20/2013John A OrwinCEOBuy15,000$11.00$165,000.00View SEC Filing  
11/20/2013Leaf Ventures I L.P. NewInsiderBuy185,978$11.00$2,045,758.00View SEC Filing  
11/20/2013Scott M RocklageDirectorBuy363,328$11.00$3,996,608.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Relypsa (NASDAQ:RLYP)
Latest Headlines for Relypsa (NASDAQ:RLYP)
Source:
DateHeadline
finance.yahoo.com logoFDA Rejects AstraZeneca’s Hyperkalemia Drug (AZN, RLYP)
finance.yahoo.com - August 23 at 10:50 AM
seekingalpha.com logoSynergy Pharmaceuticals: An Overlooked $4 Biopharma Stock - Seeking Alpha
seekingalpha.com - May 10 at 7:47 PM
investopedia.com logoFDA Rejects AstraZeneca's Hyperkalemia Drug (AZN, RLYP) - Investopedia
www.investopedia.com - March 18 at 8:22 AM
nasdaq.com logo3 Beaten Biotech Stocks That Are Set to Rebound - Nasdaq
www.nasdaq.com - February 7 at 8:23 AM
benzinga.com logoThe 7 Biggest Market Rumors Of 2016: Where Are They Now? - Benzinga
www.benzinga.com - December 22 at 2:32 AM
finance.yahoo.com logoRelypsa Announces Data on the Treatment and Impact of Hyperkalemia to be Presented at ASN Kidney Week 2016
finance.yahoo.com - November 3 at 7:10 PM
finance.yahoo.com logoGalenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies
finance.yahoo.com - September 2 at 11:59 AM
streetinsider.com logoGalenica Announces 85.6% of Relypsa (RLYP) Shares Have Been Tendered
www.streetinsider.com - September 1 at 7:01 PM
finance.yahoo.com logoGalenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa
finance.yahoo.com - September 1 at 10:13 AM
biz.yahoo.com logoRELYPSA INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Triggering Events That Accelerate or
biz.yahoo.com - September 1 at 10:13 AM
finance.yahoo.com logoRelypsa downgraded by Stifel
finance.yahoo.com - August 30 at 7:00 PM
finance.yahoo.com logo4:05 pm Relypsa announces that the Phase 4 TOURMALINE study, which evaluated the efficacy and safety of Veltassa for oral suspension with or without food for the treatment of hyperkalemia, met its primary endpoint
finance.yahoo.com - August 30 at 7:00 PM
finance.yahoo.com logoRelypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia
finance.yahoo.com - August 30 at 7:00 PM
finance.yahoo.com logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Relypsa, Inc. (RLYP)
finance.yahoo.com - August 15 at 7:32 PM
finance.yahoo.com logoRELYPSA INC Financials
finance.yahoo.com - August 12 at 7:15 PM
finance.yahoo.com logoNew details reveal Relypsa is a hot commodity
finance.yahoo.com - August 9 at 7:27 PM

Social

Chart

Relypsa (RLYP) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff